Skip to main content
PMC home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
editorial
. 2009 Oct 10;10(6):393–394. doi: 10.1007/s10194-009-0162-y

Is there an inherent limit to acute migraine treatment efficacy?

Marcelo E Bigal 1,✉, Tony W Ho 1
PMCID: PMC3476204  PMID: 19820895

Full Text

The Full Text of this article is available as a PDF (111.6 KB).

Conflict of interest

Dr. Bigal and Dr. Ho are full-time employees of Merck Research Laboratories. They own stock and stock options from Merck.

References

  • 1.Tfelt-Hansen P. Is there an inherent limit to the efficacy of calcitonin-gene related peptide receptor antagonists in acute migraine treatment? A comment. J Headache Pain. 2009 doi: 10.1007/s10194-009-0157-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–1110. doi: 10.1056/NEJMoa030505. [DOI] [PubMed] [Google Scholar]
  • 3.Tfelt-Hansen P, Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259–1287. doi: 10.2165/00003495-200060060-00003. [DOI] [PubMed] [Google Scholar]
  • 4.Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115–2123. doi: 10.1016/S0140-6736(08)61626-8. [DOI] [PubMed] [Google Scholar]
  • 5.Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304–1312. doi: 10.1212/01.WNL.0000286940.29755.61. [DOI] [PubMed] [Google Scholar]
  • 6.Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine, 2nd edn. Cephalalgia. 2000;20(9):765–786. doi: 10.1046/j.1468-2982.2000.00117.x. [DOI] [PubMed] [Google Scholar]
  • 7.Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs. other classes of acute migraine medication—a review. Cephalalgia. 2004;24(5):321–332. doi: 10.1111/j.1468-2982.2003.00690.x. [DOI] [PubMed] [Google Scholar]
  • 8.Solomon J. How strategies for managing patient visit time affect physician job satisfaction: a qualitative analysis. J Gen Intern Med. 2008;23(6):775–780. doi: 10.1007/s11606-008-0596-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007;47(4):475–479. doi: 10.1111/j.1526-4610.2007.00752.x. [DOI] [PubMed] [Google Scholar]
  • 10.Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47(3):355–363. doi: 10.1111/j.1526-4610.2006.00631.x. [DOI] [PubMed] [Google Scholar]
  • 11.Ifergane G, Wirguin I, Shvartzman P. Triptans—why once? Headache. 2006;46(8):1261–1263. doi: 10.1111/j.1526-4610.2006.00435.x. [DOI] [PubMed] [Google Scholar]
  • 12.Bigal M, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009;49:1028–1041. doi: 10.1111/j.1526-4610.2009.01410.x. [DOI] [PubMed] [Google Scholar]
  • 13.Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. N Engl J Med. 2002;346(4):257–270. doi: 10.1056/NEJMra010917. [DOI] [PubMed] [Google Scholar]
  • 14.Lipton RB, Cutrer FM, Goadsby PJ, Ferrari MD, Dodick DW, McCrory D, et al. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Curr Med Res Opin. 2005;21(3):413–424. doi: 10.1185/030079905X36387. [DOI] [PubMed] [Google Scholar]
  • 15.Recober A, Russo AF. Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007;10(8):566–574. [PubMed] [Google Scholar]
  • 16.Tepper SJ, Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr Opin Investig Drugs. 2009;10(7):711–720. [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES